Literature DB >> 2339348

Localization of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib.

Y Katagiri1, Y Hayashi, K Yamamoto, K Tanoue, G Kosaki, H Yamazaki.   

Abstract

Platelet membrane glycoprotein Ib (GPIb) functions as receptors for thrombin and von Willebrand factor (vWF) in the presence of ristocetin. To precisely locate the domains on GPIb interacting with vWF and thrombin, we prepared several peptides that have amino acid sequences analogous to that of the GPIb alpha-chain and examined their effects on ristocetin-induced (vWF-dependent) and thrombin-induced platelet aggregations. A peptide extending from residues Asp235 to Lys262 showed the strongest inhibitory effect on ristocetin-induced platelet agglutination, and a group of overlapping peptides composed of 24-28 amino acid residues representing sequences extending from Phe216 to Asp274 was found to inhibit platelet aggregation induced by thrombin. Other peptides did not inhibit platelet aggregations. Moreover, the binding to platelets of the monoclonal anti-GPIb antibody (TM60) which had been shown to inhibit both ristocetin- and thrombin-induced platelet aggregations was strongly inhibited by a peptide extending from Asp249 to Asp274. These data demonstrate that the vWF-binding domain exists in a small region between residues Asp235 and Lys262; the thrombin-interacting domain, in contrast, is located between residues Phe216 and Ala274, with a possible center of interaction in the sequence from Phe216 to Thr240 on the GPIb alpha-chain, and thrombin binding requires a relatively strict conformation in this domain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339348

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Platelet GP Ib/IX/V complex: physiological role.

Authors:  J Rivera; M L Lozano; J Corral; R González-Conejero; C Martínez; V Vicente
Journal:  J Physiol Biochem       Date:  2000-12       Impact factor: 4.158

2.  Platelet glycoprotein Ib beta/IX mediates glycoprotein Ib alpha localization to membrane lipid domain critical for von Willebrand factor interaction at high shear.

Authors:  Hongquan Geng; Guofeng Xu; Yali Ran; José A López; Yuandong Peng
Journal:  J Biol Chem       Date:  2011-04-20       Impact factor: 5.157

3.  Tokaracetin, a new platelet antagonist that binds to platelet glycoprotein ib and inhibits von Willebrand factor-dependent shear-induced platelet aggregation.

Authors:  T Kawasaki; Y Taniuchi; N Hisamichi; Y Fujimura; M Suzuki; K Titani; Y Sakai; S Kaku; N Satoh; T Takenaka
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

4.  Stable expression in Chinese hamster ovary cells of a homogeneous recombinant active fragment of human platelet glycoprotein Ib alpha.

Authors:  B Schumpp-Vonach; G Kresbach; E J Schlaeger; B Steiner
Journal:  Cytotechnology       Date:  1995       Impact factor: 2.058

5.  High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: identification of two binding domains.

Authors:  H R Gralnick; S Williams; L P McKeown; K Hansmann; J W Fenton; H Krutzsch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

6.  NH2-terminal globular domain of human platelet glycoprotein Ib alpha has a methionine 145/threonine145 amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens.

Authors:  R W Kuijpers; N M Faber; H T Cuypers; W H Ouwehand; A E von dem Borne
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

7.  Neutrophil proteinase cathepsin G is proteolytically active on the human platelet glycoprotein Ib-IX receptor: characterization of the cleavage sites within the glycoprotein Ib alpha subunit.

Authors:  D Pidard; P Renesto; M C Berndt; S Rabhi; K J Clemetson; M Chignard
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

8.  Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.

Authors:  Toshio Uemura; Tomihisa Kawasaki; Masatoshi Taniguchi; Yumiko Moritani; Kazumi Hayashi; Tetsu Saito; Jun Takasaki; Wataru Uchida; Keiji Miyata
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.